Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19107153 | 0.94 | EPHX2 (0.55) | EPHX2HTR2CPLD1 | |
| SCHEMBL18842836 | 0.89 | EPHX2 (0.48) | EPHX2CHRNB2CHRNA4HTR2CMAPT | |
| SCHEMBL26790144 | 0.86 | CYP1A2 (0.45) | — | |
| SCHEMBL10094245 | 0.86 | CYP1A2 (0.49) | MAPT | |
| SCHEMBL2609324 | 0.85 | CYP1A2 (0.51) | — | |
| SCHEMBL6111507 | 0.82 | EPHX2 (0.52) | EPHX2HTR2CPLD1 | |
| SCHEMBL14818765 | 0.81 | EPHX2 (0.54) | EPHX2CHRNB2CHRNA4HTR2CPLD1 | |
| SCHEMBL9078264 | 0.79 | EPHX2 (0.49) | EPHX2HTR2CPLD1 | |
| SCHEMBL28082095 | 0.79 | EPHX2 (0.49) | EPHX2HTR2CPLD1 | |
| SCHEMBL19107154 | 0.77 | HRH4 (0.50) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | EPHX2 2204/4885CHRNB2 3485/4885CHRNA4 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.